PTPN11 and acute myeloid leukemia: AML with mutated FMS-like tyrosine kinase 3 (FLT3), rat sarcoma (RAS), or tyrosine-protein phosphatase non-receptor type 11 (PTPN11) are associated with decreased survival and higher rates of relapse following treatment with lower-intensity venetoclax-based strategies [7-11].